^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DUET-201

i
Other names: DUET-201, CpG-STAT3siRNA, CpG-STAT3 siRNA CAS3/SS3, CAS3/SS3, CpG-STAT3 siRNA, CpG ODN/STAT3 siRNA CAS3/SS3, CpG Oligodeoxynucleotide/STAT3 siRNA CAS3/SS3, CpG/Anti-STAT3 siRNA CAS3/SS3, CpG/STAT3 siRNA CAS3/SS3, DUET-01
Associations
Trials
Company:
Scopus
Drug class:
STAT3 inhibitor, TLR9 agonist, Gene silencing
Associations
Trials
1year
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
P1, N=0, Withdrawn, City of Hope Medical Center | N=18 --> 0 | Trial completion date: Dec 2024 --> Jan 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Jan 2024
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy
|
DUET-201
over1year
Lipid Nanoparticle Formulations for the Systemic Delivery of CpG-STAT3 siRNA to Myeloid Immune Cell for Cancer Immunotherapy (ASGCT 2023)
While studies are ongoing, our results so far suggest potential species-specific differences between LNP targeting properties and underscore the need for testing in the context of human immune system in vitro or in humanized mouse models. We believe that the new LNP2PG formulation will provide vehicle for targeting human hematologic malignancies and solid tumors which rely on the tolerogenic myeloid cells for immune evasion.
Immune cell
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • TLR9 (Toll Like Receptor 9) • IFNA1 (Interferon Alpha 1)
|
DUET-201
almost2years
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
STAT3 expression
|
DUET-201
over2years
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
P1, N=18, Recruiting, City of Hope Medical Center | Initiation date: May 2022 --> Aug 2022
Trial initiation date • Combination therapy
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
STAT3 expression
|
DUET-201
over2years
Lipid Nanoparticle Formulation Enhances Gene Silencing, Immunostimulatory Properties and In Vivo Efficacy of CpG-STAT3siRNA Against Human B Cell Lymphoma (ASGCT 2022)
These studies indicated ~10-fold increase in the potency of our oligonucleotide in local administration resulting in lymphoma growth arrest. While further studies in syngeneic lymphoma models are ongoing, our data suggest that the new LNP-02 formulation of CpG-STAT3siRNA can provide an attractive new therapeutic option for the immunotherapy of B cell lymphoma and potentially certain other malignancies.
Preclinical • IO biomarker
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • IFNA1 (Interferon Alpha 1)
|
DUET-201
over2years
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
P1, N=18, Recruiting, City of Hope Medical Center | Trial completion date: Jul 2023 --> Jan 2024 | Trial primary completion date: Jul 2023 --> Jan 2024
Trial completion date • Trial primary completion date • Combination therapy
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
STAT3 expression
|
DUET-201
over3years
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (clinicaltrials.gov)
P1, N=18, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
STAT3 expression
|
DUET-201
over3years
Clinical • New P1 trial • Combination therapy
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
STAT3 expression
|
DUET-201